Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

about

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

Item

http://www.wikidata.org/entity/Q47848539

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@en

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@nl

type

Item

label

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@en

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@nl

prefLabel

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@en

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@nl

P1476

Could gonadotropin-releasing h ...... triple-negative breast cancer?

@en

P2093

Carla Strina

http://www.w3.org/2001/XMLSchema#string

Daniele Generali

http://www.w3.org/2001/XMLSchema#string

Daniele Zanoni

http://www.w3.org/2001/XMLSchema#string

Giovanni Allevi

http://www.w3.org/2001/XMLSchema#string

Manuela Milani

http://www.w3.org/2001/XMLSchema#string

Sergio Aguggini

http://www.w3.org/2001/XMLSchema#string

Silvia Paola Corona

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

P304

2473-2477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.2217/FON-2017-0272

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giandomenico Roviello

P577

2017-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29121807

http://www.w3.org/2001/XMLSchema#string